Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Comparing the Efficacy and Safety of NN1250 Once Daily When Titrated Using 2 Different Algorithms in Insulin naïve Subjects With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT01326026

Public ClinicalTrials.gov record NCT01326026. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 18, 2026, 1:16 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Trial Comparing the Efficacy and Safety of Insulin Degludec Once Daily in Insulin naïve Subjects With Type 2 Diabetes Mellitus When Titrated Using Two Different Titration Algorithms (BEGIN™: ONCE SIMPLE USE)

Study identification

NCT ID
NCT01326026
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Novo Nordisk A/S
Industry
Enrollment
222 participants

Conditions and interventions

Interventions

  • insulin degludec Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2011
Primary completion
Nov 30, 2011
Completion
Nov 30, 2011
Last update posted
Mar 5, 2017

2011

United States locations

U.S. sites
27
U.S. states
17
U.S. cities
27
Facility City State ZIP Site status
Novo Nordisk Investigational Site Birmingham Alabama 35216
Novo Nordisk Investigational Site Huntsville Alabama 35801
Novo Nordisk Investigational Site Anaheim California 92801
Novo Nordisk Investigational Site La Jolla California 92037
Novo Nordisk Investigational Site Mission Hills California 91345
Novo Nordisk Investigational Site National City California 91950
Novo Nordisk Investigational Site North Hollywood California 91606
Novo Nordisk Investigational Site San Diego California 92111
Novo Nordisk Investigational Site Golden Colorado 80401
Novo Nordisk Investigational Site Kissimmee Florida 34741
Novo Nordisk Investigational Site Tampa Florida 33603
Novo Nordisk Investigational Site Columbus Georgia 31909
Novo Nordisk Investigational Site Springfield Illinois 62711
Novo Nordisk Investigational Site Evansville Indiana 47714
Novo Nordisk Investigational Site Slidell Louisiana 70461-4231
Novo Nordisk Investigational Site Billings Montana 59102
Novo Nordisk Investigational Site Staten Island New York 10301
Novo Nordisk Investigational Site Greensboro North Carolina 27408
Novo Nordisk Investigational Site Franklin Ohio 45005
Novo Nordisk Investigational Site Melrose Park Pennsylvania 19027
Novo Nordisk Investigational Site East Providence Rhode Island 02914
Novo Nordisk Investigational Site Humboldt Tennessee 38343
Novo Nordisk Investigational Site Houston Texas 77095
Novo Nordisk Investigational Site Killeen Texas 76543-5600
Novo Nordisk Investigational Site San Antonio Texas 78224
Novo Nordisk Investigational Site Ogden Utah 84403
Novo Nordisk Investigational Site St. George Utah 84790

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 18 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01326026, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 5, 2017 · Synced May 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT01326026 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →